Clinical Trial Update: A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers [Phase 2]

View source ↗

Summary

Phase 2 trial update for a quadrivalent meningococcal tetanus protein conjugate vaccine in infants and toddlers; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Infection

Drugs mentioned

• quadrivalent meningococcal tetanus protein conjugate vaccine (bacterial meningitis vaccine conjugate)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Infection | Phase 2 | Status: COMPLETED | Results posted: 2020-06-09